**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Angela Dispenzieri, Mayo Clinic, Rochester, MN

**Main Body of the Abstract**
Background: We previously published a CA-AI-ECG model to aid in the diagnosis of cardiac amyloidosis (CA). The current study aims to determine if CA-AI-ECG predicts death and/or development of subsequent CA among MM patients undergoing ASCT.
Methods: MM patients receiving ASCT at Mayo Clinic from 7/1/2000-1/1/2023 were included in this retrospective study if they had: consented to research; no diagnosis of amyloidosis at ASCT;  a Mayo ECG within 365 days of ASCT.  Patients’ ASCTs were categorized as early (ASCT <1-year-after-diagnosis) or delayed ASCT (ASCT > 1-year-after-diagnosis). Outcomes were evaluated in the context of ECG’s meeting the threshold to CA using the CA-AI-ECG algorithm (CA-AI-ECG+).
Results: 2934 patients were included: 2367 early ASCT; and 567 delayed ASCT. 159 patients were CA-AI-ECG+: 5.6% and 4.8% in early and delayed ASCT groups, respectively.  Death within 100 days of ASCT was not higher among CA-AI-ECG+ patients. Twenty-five patients (0.9%) were diagnosed with AL amyloidosis at median of 38.2 months after ASCT and had a 3-fold higher rate of CA-AI-ECG+ pre-ASCT (p=0.043).
Overall survival was marginally worse for the CA-AI-ECG+ population (Figure) and most pronounced in the delayed ASCT population. In the delayed ASCT group, inferior survival associated with pre-ASCT CA-AI-ECG+ was independent of age, ISS,  R-ISS.
Conclusions: In a population of MM patients at an amyloidosis center, the finding of a CA-AI-ECG+ occurred in approximately 5% of patients and was associated with inferior overall survival. Further study to dissect the mechanisms of our findings and to validate them at other centers is of interest.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Angela Dispenzieri, Mayo Clinic, Rochester, MN

**Main Body of the Abstract**
**Background:** We previously published a CA-AI-ECG model to aid in the diagnosis of cardiac amyloidosis (CA). The current study aims to determine if CA-AI-ECG predicts death and/or development of subsequent CA among MM patients undergoing ASCT.
**Methods:** MM patients receiving ASCT at Mayo Clinic from 7/1/2000-1/1/2023 were included in this retrospective study if they had: consented to research; no diagnosis of amyloidosis at ASCT;  a Mayo ECG within 365 days of ASCT.  Patients’ ASCTs were categorized as early (ASCT <1-year-after-diagnosis) or delayed ASCT (ASCT > 1-year-after-diagnosis). Outcomes were evaluated in the context of ECG’s meeting the threshold to CA using the CA-AI-ECG algorithm (CA-AI-ECG+).
**Results:** 2934 patients were included: 2367 early ASCT; and 567 delayed ASCT. 159 patients were CA-AI-ECG+: 5.6% and 4.8% in early and delayed ASCT groups, respectively.  Death within 100 days of ASCT was not higher among CA-AI-ECG+ patients. Twenty-five patients (0.9%) were diagnosed with AL amyloidosis at median of 38.2 months after ASCT and had a 3-fold higher rate of CA-AI-ECG+ pre-ASCT (p=0.043).
Overall survival was marginally worse for the CA-AI-ECG+ population (Figure) and most pronounced in the delayed ASCT population. In the delayed ASCT group, inferior survival associated with pre-ASCT CA-AI-ECG+ was independent of age, ISS,  R-ISS.
**Conclusions:** In a population of MM patients at an amyloidosis center, the finding of a CA-AI-ECG+ occurred in approximately 5% of patients and was associated with inferior overall survival. Further study to dissect the mechanisms of our findings and to validate them at other centers is of interest.



Is the Cardiac Amyloidosis Artificial Intelligence Electrocardiography (CA-AI-ECG) model useful in predicting outcomes in Multiple Myeloma (MM) patients without known Amyloidosis undergoing Autologous Stem Cell Transplant (ASCT)? PA114 (#160)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.